Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists ...

Understanding the right dose of Ozempic for you can feel a bit confusing, especially if you’re just getting started. While ...

GLP-1 receptor agonists promote weight loss, which is a goal for many patients.” Despite the FDA approval of several GLP-1 ...

This month marks the 25th anniversary of the approval of Sculptra®, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCAtm) formulation.1-5,10-16 Sculptra works with ...